TY - JOUR T1 - Expression of Circulating <em>miR-155, miR-21, miR-221, miR-30a, miR-34a</em> and <em>miR-29a</em>: Comparison of Colonic and Rectal Cancer JF - In Vivo JO - In Vivo SP - 1333 LP - 1337 DO - 10.21873/invivo.11383 VL - 32 IS - 6 AU - ENIKŐ OROSZ AU - ISTVÁN KISS AU - ZOLTÁN GYÖNGYI AU - TÍMEA VARJAS Y1 - 2018/11/01 UR - http://iv.iiarjournals.org/content/32/6/1333.abstract N2 - Background: Colorectal cancer is an increasing cause of death. Circulating microRNAs (miRs) could be great diagnostic and prognostic biomarkers of colorectal cancer, but further continuation of their utility is needed for their comprehensive application. Materials and Methods: Twenty-seven patients with colonic cancer, 16 with rectal cancer and 12 healthy volunteers as controls, were involved in this study. Expression of miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a were determined by reverse transcription polymerase chain reaction (RT-PCR) from sera of patients. Results: Expression of miR-155, miR-21 and miR-221 was significantly higher in rectal cancer than in colonic cancer. There was no difference found between those with TNM1 cancer and controls for both cancer types. miR-155, miR-34a and miR-29a were down-regulated in all patients with cancer compared to controls. We did not find any statistically significant up-regulation of miR-221 in patients with colonic cancer compared to controls. In contrast, in patients with rectal cancer, miR-221 expression was higher than in controls. Advanced stage was also linked to higher miR-221 expression compared to early stage. Slight, but statistically significant increase was observed in miR-30a expression in patients with colon cancer compared to control individuals. Conclusion: Our results partly support previous findings. Here we report on differences in the expression of circulating microRNA between colonic and rectal tumours for the first time. ER -